Skip to main content
SpringerLink
Log in

Neurodegenerative Erkrankungen

Therapie der Alzheimer-Demenz — was kommt?

  • zertifizierte fortbildung
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

Zusammenfassung

Für die Therapie der Demenz vom Alzheimer-Typ befinden sich einige krankheitsmodifizierende Medikamente in der klinischen Entwicklung. Die Kosten hierfür sind jedoch hoch und die Entwicklung ist langwierig. Trotzdem sehen einige Forscher reale Chancen bis zum Jahr 2025 krankheitsmodifizierende Medikamente für die Demenz vom Alzheimer-Typ zu entwickeln.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Prince M, Wimo A, Guerchet M. World Alzheimer Report 2015. The global impact of dementia; an analysis of Prevalence, incidence, cost and trends. Online verfügbar unter http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf.

  2. Deuschl G, Maier W. S3-Leitlinie „Demenzen“. Langversion — 1. Revision, August 2015. Online verfügbar unter https://www.dgppn.de/fileadmin/user_upload/_medien/download/pdf/kurzversion-leitlinien/REV_S3-leiltlinie-demenzen.pdf.

  3. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H et al.: Defeating Alzheimer’s disease and other dementias: a priority for European science and society. In: The Lancet. Neurology 2016 15;(5): 455–532

    PubMed  Google Scholar 

  4. Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacological reports 2015: PR 67(2), S. 195–203.

    Article  CAS  PubMed  Google Scholar 

  5. Bakota L, Brandt R. Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease. Drugs 2016;76(3):301–313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Evin G. Future Therapeutics in Alzheimer’s Disease. Development Status of BACE Inhibitors. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 2016};30(3):173–194

  7. Ferreira-Vieira TH, Guimaraes I, Silva F, Ribeiro FM. Alzheimer’s disease. Targeting the Cholinergic System. CN 2016;14(1):101–115

    Article  CAS  Google Scholar 

  8. Birks J, Chong LY, Grimley E. Rivastigmine for Alzheimer’s disease. In: The Cochrane database of systematic reviews 9, 2015:, CD001191. DOI: 10.1002/14651858.CD001191.pub4.

  9. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6:37.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013;369:341–50.

    Article  CAS  PubMed  Google Scholar 

  11. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:311–21.

    Article  CAS  PubMed  Google Scholar 

  12. Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. In: Neurology 2017;88(18):1768–1775

  13. Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, Zetterberg H. Pathways to Alzheimer’s disease. J Intern Med 2014;275:296–303

    Article  CAS  PubMed  Google Scholar 

  14. Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, et al. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26 Suppl 3:321–9

    PubMed  PubMed Central  Google Scholar 

  15. Selkoe DJ. Preventing Alzheimer’s disease. Science 2012;337:1488–92

    Article  CAS  PubMed  Google Scholar 

  16. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. The Lancet Neurology 2010;9:119–28..

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. The Lancet Neurology 2013;12:207–16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rygiel K. Novel strategies for Alzheimer’s disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol 2016;48:629–36

    Article  PubMed  PubMed Central  Google Scholar 

  19. Godyń J, Jończyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 2016;68:127–38

    Article  PubMed  Google Scholar 

  20. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014;71:961–70

    Article  PubMed  PubMed Central  Google Scholar 

  21. Ayutyanont N, Langbaum JBS, Hendrix SB, Chen K, Fleisher AS, Friesenhahn M et al. The Alzheimer’s prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer’s disease treatments in presenilin 1 E280A mutation carriers. The Journal of clinical psychiatry 2014;75 (6):652–660

  22. Lannfelt L, Relkin NR, Siemers ER. Amyloid-ß-directed immunotherapy for Alzheimer’s disease. J Intern Med 2014;275:284–95

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Cummings J, Morstorf T, Lee G. Alzheimer’s drug-development pipeline: 2016. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2016;2:222–32

    Google Scholar 

  24. Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Neurology 2017;16:123–34

    Article  CAS  PubMed  Google Scholar 

  25. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008;585:97–108

    Article  CAS  PubMed  Google Scholar 

  26. Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014;63:2253–61

    Article  PubMed  PubMed Central  Google Scholar 

  27. Herrmann N, O’Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, Lanctôt KL. A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease. J Am Med Dir Assoc 2016;17:142–7

    Article  PubMed  Google Scholar 

  28. Singh M, Kaur M, Chadha N, Silakari O. Hybrids: a new paradigm to treat Alzheimer’s disease. Mol Divers 2016; 20:271–97

    Article  CAS  PubMed  Google Scholar 

  29. Forette F, Seux M, Staessen JA, Thijs L, Babarskiene M, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046–52

    Article  PubMed  Google Scholar 

  30. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch Neurol 2006;63:686–92

    Article  PubMed  Google Scholar 

  31. Meulenbroek O, O’Dwyer S, Jong D de, van Spijker G, Kennelly S, Cregg F, et al. European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer’s disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. BMJ Open 2016;6:e011584

    Article  PubMed  PubMed Central  Google Scholar 

  32. Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: The Baltimore Longitudinal Study of Aging. Neurobiol Aging 2005;26:157–63

    Article  CAS  PubMed  Google Scholar 

  33. Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease 2008; 5(3): 458–469

    CAS  Google Scholar 

  34. Bruin de NMJW, van Drimmelen M, Kops M, van Elk J, Wetering M, Middelveld-van de, Schwienbacher I. Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats. Behavioural brain research 2013: 244: 15–28.

    Article  Google Scholar 

  35. Callaghan CK, Hok V, Della-Chiesa A, Virley DJ, Upton Neil, O’Mara SM. Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457. Neuropharmacology 2012;63(5):890–897

    Article  CAS  PubMed  Google Scholar 

  36. AXOVANT (26.09.2017): AXOVANT ANNOUNCES NEGATIVE TOPLINE RESULTS OF INTEPIRDINE PHASE 3 MINDSET TRIAL IN ALZHEIMER’S DISEASE. Basel. Jonathan Neely. Online verfügbar unter http://investors.axovant.com/news-releases/news-release-details/axovant-announces-negative-topline-results-intepirdine-phase-3, zuletzt geprüft am 29.09.2017.

  37. Scott TJ, O’Connor AC, Link AN, Beaulieu TJ. Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Annals of the New York Academy of Sciences 2014;1313:17–34

    Article  PubMed  PubMed Central  Google Scholar 

  38. Winter Y, Oertel WH, Dodel R. Is there underfunding in brain research? The UK research expenditure. Eur J Neurol 2012;19:4–5

    Article  PubMed  Google Scholar 

  39. Relkin N. Clinical trials of intravenous immunoglobulin for Alzheimer’s disease. Journal of clinical immunology 2014;34 Suppl 1:74–9

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Essen, Deutschland

    Michael Hosch, Lioba Klaas, Annika Welchar, Marie Louise Aicher, Benedikt Obermaier, Vinona Wicht &  Richard Dodel

  2. Lehrstuhl für Geriatrie, Universitätsklinik Essen, Universität Duisburg-Essen, Elisabeth-Krankenhaus Geriatriezentrum Haus Berg, Contilia GmbH, Germaniastr. 1 - 3, 45356, Essen, Deutschland

    Richard Dodel

Authors
  1. Michael Hosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lioba Klaas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Annika Welchar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marie Louise Aicher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Benedikt Obermaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vinona Wicht
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard Dodel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Dodel.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen und im Zusammenhang mit diesem Beitrag keine Interessenkonflikte bestehen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hosch, M., Klaas, L., Welchar, A. et al. Therapie der Alzheimer-Demenz — was kommt?. InFo Neurologie 19, 36–44 (2017). https://doi.org/10.1007/s15005-017-2086-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-017-2086-4

Search

Navigation